Ravi Savarirayan

The Ethics of Growth-Promoting Pharmaceuticals for Achondroplasia

In 2021, vosoritide became the first pharmaceutical approved to treat the pathophysiology of achondroplastic dwarfism. It has generated significant ethical debate. Proponents emphasize its potential to improve quality of life and functional independence, whereas critics raise con...